Integrins link the inside of a cell with its outside environment and in doing so regulate a wide variety of cell behaviors. Integrins are well known for their roles in angiogenesis and cell migration but their functions in bone formation are less clear. The majority of integrin signaling proceeds through focal adhesion kinase (FAK), an essential component of the focal adhesion complex. We generated transgenic mice in which FAK was deleted in osteoblasts and uncovered a previously unknown role in osteoblast differentiation associated with bone healing. FAK mutant cells migrated to the site of skeletal injury and angiogenesis was unaffected yet the transgenic mice still exhibited numerous defects in reparative bone formation. Osteoblast differentiation itself was unperturbed by the loss of FAK, whereas the attachment of osteoclasts to the bone matrix was disrupted in vivo. We postulate that defective bi-directional integrin signaling affects the organization of the collagen matrix. Finally, we present a compensatory candidate molecule, Pyk2, which localized to the focal adhesions in osteoblasts that were lacking FAK.
Introduction
Integrins function as cell-substrate adhesion molecules, serving as receptors for major extracellular matrix molecules including collagens and fibronectin [1] [2] [3] [4] . In addition to their adhesive functions, integrins mediate bi-directional signaling between the extracellular matrix and the cell. Upon activation of integrin molecules, cytoskeletal and signaling molecules are recruited into focal adhesion structures [5] [6] [7] .
Although integrin molecules provide a platform for the signaling complex, they do not have intrinsic enzymatic activities in their cytoplasmic domains [8] . Therefore, transmission of downstream signals has to be mediated by non-receptor tyrosine kinases, such as FAK or Src family kinases [9] . Integrin mediated attachment activates FAK by autophosphorylation at tyrosine 397, which provides a binding site for Src [10, 11] . In turn, FAK binds to a number of signaling molecules. For example, the N-terminal domain of FAK binds to Shc [12] . The C-terminal domain of FAK binds to Talin and Paxillin [13, 14] , which link the integrin-FAK signaling complex to the actin cytoskeleton [15, 16] . Furthermore, FAK is required for the phosphorylation of Src and other downstream targets [17, 18] . Since several different integrins transduce signals via FAK [19, 20] , the deletion of FAK is one mechanism to cause a major reduction in integrin signaling within a cell population.
The role of FAK in bone formation, remodeling and repair in vivo is unknown, because deletion of FAK in the mouse germline results in embryonic death at e8.5-9.0 [21] , long before the skeleton forms. Our goal was to understand in greater detail the role of FAK in these essential stages of osteogenesis in vivo. To that end, we generated a conditional deletion of FAK using a Cre-loxP approach by crossing mice, in which the Cre recombinase is driven by 2.3 kb of the collagen type I(α)I promoter, with mice carrying a floxed FAK allele [22, 23] . In this study, we first established immortalized calvarial osteoblast and bone marrow cell lines which are devoid of FAK and assayed them for their ability to differentiate into osteoblasts. Second, we investigated the function of FAK in adult bone regeneration. Lastly, we explored a possible compensatory role for the closely related non-receptor type kinase, Pyk2, in osteoblast differentiation when FAK is not present.
Materials and methods

Mice and genotyping
All the procedures for animal breeding and surgeries followed the approved protocols and guidelines from the Administrative Panel for Laboratory Animal Care (APLAC) at Stanford University and the Laboratory Animal Resource Center (LARC) at UCSF. Heterozygote transgenic mice containing loxP sequences (floxed FAK) in the flanking introns of the second kinase domain of fak were generated [23] and crossed with FAK heterozygote mice (FAK +/− ) [21] to obtain FAK fl/− and FAK fl/fl genotypes. Transgenic mice carrying Cre recombinase driven by the 2.3 kb collagen type I(α)I promoter (Cre +/− ) [22] were crossed with FAK fl/− and FAK fl/fl mice. Floxed fak and the recombined allele resulting from Cre recombinase activity were differentiated using P1 (5′-gagaatccagctttggctgttg-3′) and P2 (5′-gaatgctacaggaaccaaataac-3′) PCR primers. Genotyping was performed by tail biopsy followed by PCR.
Antibodies
Anti-mouse FAK antibody was obtained from Transduction Laboratories (San Jose, CA). Rabbit antibody against phophospecific Pyk2-402P was purchased from Biosource (Camarillo, CA). β-Actin antibody was purchased from Sigma (AC-15). Biotinylated-monoclonal Cre antibody was obtained from Abcam (ab24580; Cambridge, MA). Antibodies were used at 1:1000 and 1:100 for Western blot. Secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).
Calvarial osteoblast and bone marrow cell isolation
In order to generate cell lines in which the fak allele was deleted, two different transgenic mouse lines were generated. [24, 25] .
Clonal cell line establishment and in vitro differentiation
Primary cells from calvaria and bone marrow were grown in 15% FBS α-MEM, which consisted of minimum medium with α-modification, supplemented with 15% fetal calf serum (Hyclone, Logan, Utah) and 1% penicillin/ streptomycin (Gibco BRL, Gaithersburg, MD). Cells were infected at an MOI 10 with adenovirus carrying cre and gfp under regulation of the CMV promoter (Ad-cre) [23] . Single cell clones that maintained cre expression were identified using primers of cre1 (5′-cctggaaaatgcttctgtcctttgcc-3′) and cre2 (5′-gagttgatagctggctggtggcagatg-3′). These clones were removed from the study. Single cell cloning was performed using a limited dilution and individual clones were established as cell lines. Control FAK fl/fl calvarial and bone marrow cells that were not treated with adeno-cre were handled in a similar manner. The differentiation of skeletal progenitor cells into osteoblasts was induced with ascorbic acid (56 mM) and β-glycerophosphate (5 mM) in vitro. The media were changed every 48 h for 2 weeks. Osteoblast differentiation was determined by 0.2% Alizarin Red staining.
Western blot and immunofluorescence
Detailed procedures were described previously [26] . Protein concentration was determined by BCA method [27] . One microgram of total protein was loaded on each lane for Western blot analysis. Proteins were transferred onto nitrocellulose membranes and blotted with the appropriate primary antibodies. Bands were visualized using an enhanced chemiluminescent kit (Amersham, Piscataway, NJ). β-Actin was used to confirm equal amount protein loading. For immunofluorescence, fluorescein-conjugated donkey IgG was used to detect signals under an epifluorescence microscope (Zeiss, Germany). Nuclei were stained with Hoechst 33342 dye (Invitrogen, Carlsbad, CA) prior to mounting.
Histology, immunohistochemistry and whole mount skeletal staining
Tissues were harvested at different time points and embedded in paraffin. Sections were cut at 7 μm thickness. For histology, sections were stained using Movat's pentachrome [28] . Tartrate resistant acid phosphatase [29] staining procedure was previously described [30] . For Cre immunohistochemistry, tissue sections were permeabilized with cold acetone for 10 min followed by overnight incubation with the primary antibody. After streptavidin-HRP incubation (1:2000) , signal was detected using a DAB kit (Vector lab, Burlingame, CA). Whole mount skeletal staining with Alizarin Red and Alcian Blue was performed according to previous reports [31] . Proliferating cell nuclear antigen (PCNA) staining followed the manufacturer's instruction (Zymed, San Francisco, CA). Nuclei were stained with Hoechst 33342 dye (Invitrogen, Carlsbad, CA) prior to mounting.
Generation of fak probes and in situ hybridization
The N-terminal FAK probe was made by digesting mouse FAK cDNA with ClaI and XhoI and ligating the resulting fragment into pBluescript. A SmaI and XbaI fragment of FAK cDNA was ligated into pBluescript to generate the Cterminal region of the FAK probe. Probe sequences were verified by DNA sequencing. Digoxigenin-labeled probes for both the N-and C-terminal portions of FAK were transcribed with T3 RNA polymerase and used for in situ hybridization [32] .
Surgical procedures
Previously, we described the healing process following pinhole injury in mouse tibiae [33] . Briefly, mice were anesthetized and the anterior-proximal tibia was exposed. Injuries were made using a Dremel® drill with a 1 mm core drill bit (Racine, WI). Wounds were closed and animals received Buprenorphine for analgesia. Animals were allowed to ambulate freely after recovery. For the bone chip experiment, murine tibiae were isolated and snap-frozen in liquid nitrogen followed by trituration with a mortar and pestle. Then, the bone chips were transplanted into the tibial pinhole injury and the wound was closed. Animals were sacrificed at post-surgical day 7, 14, 21, and 28.
Results
FAK null cells can differentiate into osteoblasts
Extracellular matrix signals are required for osteoblast differentiation [34] [35] [36] , and one class of molecules that might mediate this extracellular signaling are the integrins. Our first objective was to determine if integrin signaling, specifically via FAK, was essential for osteoblast differentiation. Along with other investigators, we have shown that function-blocking antibodies to integrins resulted in a significant reduction in formation of mineralized nodules in vitro [35] [36] [37] . These findings suggest that integrin signaling is necessary for the differentiation of progenitors into osteoblasts. There are, however, caveats to these types of in vitro experiments. The most obvious limitations are related to the specificity and/or efficacy of the function-blocking antibodies [38] and the inability to directly assess integrin activity. One read-out of integrin function is the state of ERK phosphorylation [39] , but it is an indirect measure and therefore may not be the most accurate indicator of integrin activity.
To circumvent these limitations, we employed a genetic strategy for significantly reducing integrin signaling, in which FAK was inactivated by crossing FAK fl/− and FAK fl/fl mice with p53 null mice to generate FAK fl/fl ;p53 −/− and FAK fl/− ;p53 −/− double transgenic mice. Cells were then isolated from neonatal calvaria or from adult bone marrow of these mice and transduced with an adenovirus carrying cre to eliminate functional FAK gene expression. The adenovirus construct contained gfp under the control of an internal ribosomal entry site, which allowed us to evaluate the infection efficiency using GFP expression. We found that Cre protein levels gradually increased during the first 72 h and then tapered off (Fig. 1A) . Concomitant with Cre expression was a gradual loss of FAK, which was substantially reduced by d5 (Fig. 1A ). FAK null clones (n = 35 from calvarial osteoblasts, and n = 22 from bone marrow) were then established and the absence of FAK was verified using Western blot (Fig. 1B) . The inactivation of p53 ensured that these cell lines were genetically immortalized [21] .
Clones from FAK fl/fl ;p53 −/− served as positive controls (n = 28 from calvarial osteoblasts, and 33 from bone marrow), and any FAK null clones that contained chromosomal cre were identified by PCR and then removed from further study.
With these reagents in hand we undertook a series of assays to test whether or not FAK null clones could differentiate into osteoblasts. Using clones derived from calvarial osteoblasts and from the bone marrow, we found that a majority of the clones (14/20, 70%) from both sources could not differentiate into osteoblasts (Figs. 1C, D, red labels). Conversely, 30% of FAK null clones could differentiate into osteoblasts when grown in osteogenic media (6/20; Figs. 1C, D, green labels). When wild type clones were challenged to differentiate, 8 out of 12 clones could differentiate (data not shown). These results suggest that while the majority of FAK null cells could not complete their differentiation into osteoblasts, a minority of FAK mutant cells could. Furthermore, results were comparable whether the source of the osteoprogenitor cells was the calvaria or the bone marrow ( Fig. 1 and data not shown). This discrepancy raised a question whether FAK, and therefore integrin signaling, was essential for osteoblast differentiation. An abundant literature, however, implicates integrin signaling in the program of bone formation [40] [41] [42] [43] . We decided to take another tactic that used the well characterized collagen type I promoter [44] to drive Cre expression and thus block FAK activity in developing embryos.
FAK inactivation in osteoprogenitor cells did not disrupt fetal skeletogenesis
Collagen type I is the predominant extracellular matrix protein in bone [45] . The 2.3 kb fragment of the collagen type I(α)I promoter specifically drives expression in mature osteoblasts, and by crossing floxed FAK mice with Cre mice containing the 2.3 kb promoter of collagen type I(α)I we generated mice carrying Cre + ;FAK fl/fl and Cre + ;FAK fl/− genotypes. We confirmed that Cre-mediated recombination resulted in FAK inactivation by optimizing a PCR that amplified the intervening sequence between the two loxP sites. When Cre recombinase was active, the distance between the two PCR primers P1 and P2 was shortened ( Fig. 2A) . A typical genotyping PCR result showed the wild type allele (fl, 1.6 kb) compared to the recombined allele (rec; 327 bp; Fig. 2B ). Hereafter, we refer to these mice as FAK mutants.
Given in vitro evidence describing an essential role for integrin signaling in osteoblast differentiation, we were surprised to find that FAK mutant embryos had an intact skeleton. We examined mice at a variety of embryonic stages (e.g., from e13.5 through post-natal and adult life) and despite careful histological staining, whole mount analyses, X-ray, and micro CT, we did not detect differences in patterning of the skeleton nor in the onset, rate, or extent of bone formation. For example, we inspected the fetal skeleton for discrepancies in the commitment or allocation of cells to chondrogenic and osteogenic lineages and failed to detect any differences (Figs. 2C, D). The patterning and overall growth of the skeleton were indistinguishable between wild type and FAK mutants (Figs. 2E, F). We also monitored the growth of the juvenile and adult skeletons, as well as the architecture of the growth plates, and found no differences between wild type and FAK mutants (Figs. 2G, H). In addition, we examined bones that form through intramembranous ossification and failed to uncover any detectable alterations (data not shown). These analyses suggested that the loss of FAK is not critical for osteoblast differentiation in vivo. An alternative possibility is that FAK activity may only be transiently required and that other signaling pathways replace its function during fetal skeletogenesis. To separate out this potential redundancy we turned to an examination of the adult FAK mutant skeleton, reasoning that a subtle defect in osteoblast differentiation might manifest itself as a disruption in skeletal repair.
Acute injury in adult skeleton initiated FAK signaling
Adult bone formation is an integral component of skeletal remodeling and adult bone formation is greatly enhanced in response to a skeletal injury. We therefore generated small, mono-cortical tibial injuries in adult mutant mice in order to test whether the absence of FAK adversely affected bone regeneration.
Since fak has multiple splicing forms in vivo [46, 47] we used in situ hybridization to show where FAK transcripts were originally expressed in the adult skeleton, and where the gene had been deleted. cDNA probes were generated against the Nand C-terminal portions of FAK (Fig. 3A) to show that the Cre mediated recombination effectively deleted fak in collagen type I-expressing osteocytes (Figs. 3B, C) . The C-terminal probe, however, recognized a truncated FAK gene in osteocytes (Figs. 3D, E), which generates the FAK related non-kinase protein, FRNK [48, 49] . FRNK lacks the kinase domains of FAK which mediate most of signaling functions of FAK [50] . ) were treated with adenovirus carrying cre. One microgram of total protein lysates was analyzed by Western blot using a monoclonal antibody against Cre. Signal was detected using enhanced chemiluminescence. After 5 days, the Cre protein level was tapered off. The same lysates were subjected to Western blot using a monoclonal antibody against FAK. Immortalized calvarial FAK null clones were induced to differentiate in vitro. Cells were grown to confluency and differentiation was induced using ascorbic acid and β-glycerophosphate. 
Loss of FAK results in delayed bone regeneration
We confirmed that in FAK mutants collagen type I (col I), a molecular marker of osteoprogenitor cells [51, 52] continued to be expressed in the intact adult skeleton (Fig. 4A) and that the Cre protein co-localized with col I expression in the periosteum (Fig. 4B) , and in col I-expressing osteocytes. The co-expression of runx2 and sox9 in the periosteum (Figs. 4C, D) indicated that at least some of the cells in which FAK was inactivated were osteoprogenitor cells [53] [54] [55] . We generated mono-cortical defects in the tibiae of FAK mutants and wild type mice and then examined the healing response over a protracted time course. We first confirmed that FAK was inactivated in cells that contributed to bone repair. In FAK mutants, col I was strongly expressed in cells occupying the injury site (Fig. 4E ) and this expression coincided with Cre immunostaining in the injury site (Fig. 4F) . Thus the injury site was populated by osteoprogenitor cells deficient in FAK.
We next evaluated how FAK deletion affected skeletal repair over the course of healing. On post-surgical d7, wild type cells in the injury site had differentiated into osteoblasts and deposited a bony matrix intermingled with new blood vessels (n = 4; Fig. 5A and data not shown) . In FAK mutants, however, there was no evidence of a bony matrix (n = 4; Fig. 5B) .
By post-surgical d14, a bony bridge spanned the cut cortices in wild type mice. In FAK mutants a bony matrix was evident but was insufficient to bridge the defect (n = 3 for both wild type and mutants; Figs. 5C, D) . At post-surgical d21, the amount of bone in the injury site was roughly equivalent between wild type and FAK mutants, indicating that FAK deletion delayed, but ultimately did not prevent, the deposition of a matrix that underwent mineralization (n = 3; Figs. 5E, F) . At post-surgical d28, wild type injury sites had undergone extensive bone remodeling (n = 4 for both wild type and mutants; Fig. 5G ). FAK mutants, on the other hand, developed large bony calluses compared to wild type counterparts and retained new bone in the marrow cavity (Fig. 5H) .
To identify the mechanisms for delayed bone healing in FAK mutants, we performed a series of experiments. First, we examined alkaline phosphatase activity in the injury sites at post-surgical d7. Wild type animals showed significantly higher alkaline phosphatase activity than FAK mutants in the injury sites (Figs. 5I, J) . Next, immunostaining for PECAM in the injury sites showed no obvious difference in wild type and FAK mutants (Figs. 5K, L) . Since FAK is involved in cell proliferation [56] , a proliferative defect might be responsible for fewer osteoblasts in the injury site. Therefore, we performed PCNA immunostaining of the injury sites at post-surgical d7. Both wild type and FAK mutant mice showed a similar proliferative activity (Figs. 5M, N) . By post-surgical d14, however, both wild type animals and FAK mutants showed comparable alkaline phosphatase in the injury sites (Figs. 5O, P) suggesting that osteoblast differentiation in FAK mutant mice was recovered. Together, these analyses demonstrate that the initial lack of a bony matrix was more likely due to a delay in osteoblast differentiation. 
Bone matrix deposited by FAK mutant osteoblasts is defective
Almost as soon as new bone is deposited in an injury site, osteoclasts begin to remodel the matrix. We found evidence of abundant TRAP activity in wild type injury sites, in keeping with the exuberant remodeling that is characteristic of repair (Fig. 6A) . In FAK mutant injury sites, osteoclast activity was low at post-surgical d7 (Fig. 6B) , which further supported our conclusion that new bone deposition was delayed in mutants. At all time points examined (i.e., postsurgical d7, 14, 21, and 28) we observed diminished TRAP activity (Figs. 6C, D) .
Thus, our analyses demonstrate that FAK inactivation hampers the program of bone regeneration and remodeling. Initially, loss of FAK impedes the deposition of a mineralized matrix; with time, this defect is overcome, but a delay in osteoclast remodeling of the mutant extracellular matrix then hinders the latter stages of bone regeneration. Our genetic strategy, however, drives FAK inactivation in collagen type Iexpressing osteoblasts and not in osteoclast precursors (Fig. 2) . Was there some mechanism by which osteoclasts became defective in the adult animal? Or was the defect in bone regeneration due to perturbations in the deposition or organization of the extracellular matrix in the FAK mutant? We devised another method to independently assess the in vivo activity of osteoblasts and osteoclasts in another adult repair scenario.
We first tested whether osteoclasts from FAK mutant mice were defective in their ability to attach and remodel bone matrix. In a previous study, we demonstrated that bone matrix implanted into a mono-cortical defect serves as an excellent scaffold for osteoblasts to attach and deposit a mineralized matrix. Concomitant with this exuberant osteoblast activity is enhanced osteoclast remodeling of the implanted matrix [33] . Therefore, we prepared bone chips from wild type and mutant tibiae using a preparation that kills osteocytes and osteoblasts in the bone chips but leaves the mineralized matrix intact [57] . Next, mono-cortical defects, identical to those generated in our earlier experiments, were prepared in wild type and FAK mutant mice. Wild type bone chips were introduced into wild type injury sites (n = 3; Fig. 6E ), and wild type bone chips were placed into FAK mutant injury sites (n = 4; Fig. 6F ). Likewise, FAK mutant bone chips were introduced into wild type injury sites (n = 3; Fig. 6G ), and FAK mutant bone chips were placed into FAK mutant injury sites (n = 3; Fig. 6H) . The response was then examined at post-surgical d7.
Abundant TRAP activity was evident around wild type bone chips implanted in wild type injury sites (Fig. 6E) , confirming the exuberant bone remodeling that characterizes this assay. When wild type bone chips were introduced into FAK mutants, we also noted an equivalent TRAP activity (Fig. 6F) , indicating that the intrinsic activity of osteoclasts in mutant animals was not affected by the loss of FAK. In contrast, when attempting to remodel FAK mutant bone chips, wild type osteoclasts as well as osteoclasts from FAK mutant mice showed diminished activity (Figs. 6G, H) , demonstrating that the matrix in FAK mutant animals was not suitable for remodeling by osteoclasts from either source. These data support the conclusion that the organization of the mineralized matrix and not the osteoclasts was defective in FAK mutant mice. To confirm that the TRAP positive cells were osteoclasts, we performed a double staining for TRAP and nuclei. Our data showed that TRAP positive cells in the injury site were multi-nucleated, a typical feature of osteoclasts. In addition, the results showed that osteoclasts in the FAK mutant attached to wild type bone chips, whereas osteoclasts failed to adhere to mutant bone chips in vivo (Figs.  6I, J, arrows) .
When considered together, our data indicate that FAK mutant osteoblasts fail to secrete a bony matrix in a timely fashion. Even though the FAK mutant matrix eventually becomes mineralized, it still does not serve as a favorable substrate for osteoclast attachment and remodeling. Consequently, there is a delay in remodeling the FAK mutant matrix. Collectively, these defects culminate in delayed bone regeneration. 
Pyk2 may substitute for FAK in vitro for osteoblast differentiation
By examining the program of skeletal repair in FAK mutant mice we gained insight into one compensatory mechanism that might compensate for the loss of FAK during osteoblast differentiation. One candidate molecule that may replace FAK function is Pyk2 kinase, which shares ∼ 45% sequence homology with FAK [58] . Functionally, Pyk2 can partially replace FAK in cell migration assays [41] and spreading [59] . We returned to the FAK null cell lines we had generated (Fig. 1) and evaluated a subset of them for evidence of altered Pyk2 activation of localization.
When Pyk2 is activated, tyrosine 402 of Pyk2 is phosphorylated and this form of the protein can be detected with a phospho-specific antibody [60] . Western analyses showed that the level of total Pyk2 was decreased in FAK null cells (Fig. 7A,  lanes 2 and 3) . The level of activated Pyk2, however, was increased in these cells (Fig. 7B, lanes 2 and 3) .
We then used cytohistochemistry to compare localization of Pyk2 in wild type cells. Pyk2 was localized in perinuclear region in wild type cells. In contrast, in FAK null cells Pyk2 was redistributed. The punctated pattern of Pyk2 staining suggested that, in the absence of FAK, Pyk2 relocated to the focal adhesions (Figs. 7C, D) . The same punctated staining pattern was observed using an FAK antibody in wild type cells (Fig. 7E) , lending further support to our hypothesis that Pky2 protein occupied a new cellular location when FAK was deleted. Finally, we used an antibody against phosphoPyk2 to show that activated Pyk2 was present at focal adhesion sites in FAK null osteoblasts (Fig. 7F) . Taken together, these in vitro data indicated that functional Pyk2 relocated to the focal adhesions when FAK was deleted, where it could functionally substitute, at least in part, deleted FAK.
Discussion
FAK is not required for osteoblast differentiation in vitro
An abundant literature implicates integrin signaling in osteoblast differentiation but most of these data are obtained from in vitro assays. For example, a variety of integrins are expressed on the osteoblast cell surface and function-blocking antibodies to these integrins reduce osteoblast differentiation in vitro [34] [35] [36] 61, 62] . Chemicals that block potential downstream targets of integrin signaling, such as ERK and RAF, inhibit osteoblast differentiation in vitro [42, [63] [64] [65] .
Our in vitro results with immortalized FAK null osteoblasts (i.e., FAK fl/fl ;p53 −/− calvarial and bone marrow osteoblasts), however, produced contradictory results. While the majority of FAK null cells did not differentiate into osteoblasts, 30% of them did. Our first thought was that these cells might have lost their potential to differentiate after prolonged culturing. We found, however, that freshly isolated calvarial osteoblasts from FAK mutant mice could also differentiate into osteoblasts. These data demonstrate that FAK may not be critical for osteoblast differentiation. 
Generation of FAK conditional knockout mice in mature osteoblasts
Previous genetic studies have failed to shed light on the role of integrins in osteogenesis because most integrin mutants either die before osteoblast differentiation ensues (i.e., β 1 and α5 integrin null mutants; [76, 77] or the mutants are born and exhibit no skeletal phenotype (i.e., α 1 β 1 or α 2 β 1 integrin mutant; [78, 79] .
We undertook an alternative approach that circumvented early lethality and targeted significant disruption of integrin signaling to osteoblasts, the cells that deposit the bony matrix of the skeleton. We exploited the fact that when integrins bind to the extracellular matrix, FAK is activated [66] . Therefore, perturbation of FAK in collagen type I-expressing cells appeared to be an effective method to inhibit most, if not all, integrin signaling involved in osteoblast differentiation.
We used a Cre-loxP system to generate a conditional knockout of FAK, using the well characterized collagen type I(α)I promoter. Three fragments of the promoter have been used to generate transgenic mice [22, 44, 67] ; among these, the 2.3 kb Col I promoter fragment is specific for bone cells, although it is activated after osteoblast differentiation is initiated [51] .
Using floxed FAK mice and 2.3 kb collagen I-Cre mice, we generated mutants in which FAK is silenced in osteoblasts. FAK mutants did not express full-length fak transcripts but did express a truncated form of FAK, FRNK (Fig. 3) . FRNK in FAK mutants, however, is defective in many aspects of integrin signaling because it lacks the kinase domain and autophosphorylation site which are essential for its activation and subsequent binding of Src [48] . We could not rule out the possibility that even after gene deletion pre-existing fak transcripts remained functional in the osteoblasts of Cre + ; FAK fl/fl mutants [68, 69] . To minimize any potential contribution from residual FAK and to achieve efficient Cre recombination, we introduced a fak null allele into the colony and generated a second line of transgenics (Cre + ;FAK fl/− ). Detailed histological analyses of FAK mutants from embryonic stages to adulthood in both lines showed the same normal skeletal anatomy and morphology (Fig. 2) .
FAK mutants show delayed bone healing and remodeling
Because FAK is involved in both cell cycle progression and migration, adult skeletal repair represented a particularly attractive model in which to re-assess the role of FAK in osteoblast differentiation and skeletal progenitor migration. We evaluated the role of FAK in skeletal regeneration by generating small skeletal injuries in FAK mutants and their wild type counterparts.
The first and most obvious observation we made was that FAK mutant mice healed their skeletal injuries by generating new bone (Fig. 5) . This confirmed the ability of cells to differentiate into osteoblasts in the absence of FAK-mediated integrin signaling. There was, however, a defect in this bone regeneration in FAK mutants. They were slow in depositing the extracellular matrix that could undergo normal mineralization (Fig. 5) . In addition, FAK mutants generated larger calluses than wild type animals during the process of skeletal healing. These observations prompted us to investigate the ability of bone remodeling in FAK mutants.
Bi-directional integrin signaling is disrupted in FAK mutants
To identify the defects in bone remodeling in FAK mutants, we undertook a second assay in which bone chips were implanted into injury sites (Fig. 6) . In this preparation of bone chips any contribution from living cells is nullified during the freezing step; however, the procedure leaves the bone matrix intact. This second assay confirmed that osteoclasts in FAK mutants are not defective since they could remodel the bone chips from wild type animals. On the contrary, both wild type and FAK mutant osteoclasts could not bind and remodel FAK mutant collagen matrix as efficiently as they could bind to and remodel wild type matrix (Fig. 6 ). These data strongly suggest that bone matrix in FAK mutant is not favorable for osteoclast binding in vivo.
To date, there is little evidence showing that integrin signaling can modulate collagen matrix organization in osteoblasts. The present study supports that idea and suggests that FAK-dependent bi-directional signaling between the inside osteoblast and the outside affects extracellular matrix organization. Thus, we propose that a loss of FAK in osteoblasts affects their ability to properly organize the collagen-rich matrix they secrete; consequently, osteoclasts cannot properly attach to and remodel the defective matrix as efficiently as they do with wild type matrix.
Pyk2 may compensate for FAK in osteoblast differentiation
FAK does not appear to be critical in the late stages of osteoblast differentiation, but the possibility exists that other closely related molecules, such as Pyk2, compensate and thus obscure the requirement for FAK. For example, upon integrin activation FAK is recruited to focal adhesions in cells, a step that is mediated by the focal adhesion targeting (FAT) domain in the C-terminus of FAK [70] . FAK contains binding sites for other signaling molecules, which stabilize the entire signaling complex in the focal adhesion [4] . Targeting FAK into different locations in the cells resulted in the destabilization of the signaling complex mediated by integrin and FAK [50, 71] . Therefore, the localization of FAK in the focal adhesion is an important factor for its full activation [72] .
Pyk2 is localized to the perinuclear region [70, 73, 74] , and over-expression of Pyk2 causes its translocation to focal adhesions with low efficiency [70] . In FAK null osteoblasts, however, Pyk2 spontaneously localizes to the focal adhesions, where it is present in its active form (Fig. 7) . Pyk2 at the focal adhesion may subsume some of the functions of the deleted FAK and thus mask a further requirement for FAK in the process of osteoblast differentiation.
In summary, our data underscore the complex interactions between cells and their extracellular matrix that are integral to the process of differentiation and tissue repair. These data indicate that FAK is not a critical requirement for the differentiation of mesenchymal precursor cells into osteoblasts. However, once osteoblasts secrete their collagen type I, FAK dependent integrin signaling appears to be critical for the structural protein to become organized into a fibrillar network. If the osteoid matrix is defective, then remodeling of the matrix may also be disrupted. Such is the case in the FAK mutants here, where osteoclasts do not appear to be able to bind and remodel the matrix as efficiently as they remodel wild type bone matrix.
